Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Daxor Corporation (DXR:NASDAQ), powered by AI.
Daxor Corporation is currently trading at $10.00. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Daxor Corporation on Alpha Lenz.
Daxor Corporation's P/E ratio is 5.4.
“Daxor Corporation trades at a P/E of 5.4 (undervalued) with strong ROE of 22.5%. 3Y revenue CAGR of 17.8% highlights clear growth momentum.”
Ask for details →Daxor Corporation is a medical instrumentation and biotechnology company focused on providing innovative solutions for blood volume analysis. Its primary product, the Blood Volume Analyzer (BVA-100), is a diagnostic tool used to precisely quantify the blood volume status of patients. This capability assists healthcare professionals in making informed decisions regarding fluid management, which is critical in treating conditions such as heart failure, hypertension, and trauma. Daxor's technology plays a vital role in enhancing patient outcomes and optimizing treatment in both surgical and intensive care settings. The company's contributions are significant in the healthcare sector, where accurate patient monitoring can have life-saving implications. Headquartered in New York, Daxor also actively engages in ongoing research and development to expand the applications of its patented technology, aiming to address unmet needs in patient care. Within the financial market, Daxor represents a niche player in the biomedical devices and diagnostics industry, drawing interest from investors who focus on innovative healthcare technologies. Its role in enhancing diagnostic accuracy underscores its importance in the medical field."}
“Daxor Corporation trades at a P/E of 5.4 (undervalued) with strong ROE of 22.5%. 3Y revenue CAGR of 17.8% highlights clear growth momentum.”
Ask for details →Daxor Corporation (ticker: DXR) is a company listed on NASDAQ in the Healthcare sector (Medical Instruments & Supplies). Market cap is $50M.
The current price is $10 with a P/E ratio of 5.44x and P/B of 1.09x.
ROE is 22.45%. Annual revenue is $10M.